The spatiotemporal trend of renal involvement in COVID-19: A pooled analysis of 17 134 patients

Abstract

Background The spatiotemporal trend of renal involvement in Coronavirus Disease 2019(COVID-19) patients is still unclear. Therefore, we seek to reveal the dynamics of renal involvement superimposed COVID-19 according to time and space. Methods The COVID-19 patients reporting the renal involvement were enrolled in our study. We collected the following information: the first author, patient demographics, patients enrolled period, location, definition of acute kidney injury (AKI), prevalence of AKI and renal replacement treatment (RRT). Results 17,134 patients were included finally. The overall prevalence of AKI in COVID-19 patients was 19%, which 7% of them underwent RRT. And the overall risk of AKI in patients enrolled before March 1, 2020 (9%) was significantly lower than that after March 1, 2020 (36%) (P < 0.00001). Moreover, the overall risk of AKI outside Asia (35%) was significantly higher than that in Asia (10%) (P < 0.00001). Additionally, similar to patients required RRT, AKI patients would more tend to become seriously ill or even die (P < 0.00001). Conclusions This study firstly reports that renal involvement superimposed COVID-19, a comorbidity portending a poor prognosis, has become an increasingly serious problem over time, and more common outside Asia. Thus, more concerns should be offered to manage the specific group of patients.

Long COVID: A Molecular, Cellular and Histopathology Overview

“…(2021) showed that of 17,134 individuals with COVID-19, about 19% had acute kidney injury and 7% required renal replacement therapy [81]. A similar profile was found by Oweis et al ( 2022) in a cohort conducted in Jordan with 1044 patients, of whom 25.3% developed acute kidney injury and 1.8% were referred for renal replacement therapy [82].…”

Compromiso renal en pacientes con COVID-19 severa y crítica

“…Un análisis temporoespacial del compromiso renal en el contexto de pacientes con COVID-19 consideró 17.134 pacientes de 30 estudios seleccionados (18) . La prevalencia de IRA en los pacientes enrolados antes del 1/3/20 fue significativamente menor que la de los pacientes enrolados en forma posterior (9% versus 36%) (18) . Los pacientes con COVID-19 severa y los no sobrevivientes presentaron un riesgo significativamente mayor de desarrollar IRA y de necesidad de TRR (18) .…”

“…La prevalencia de IRA en los pacientes enrolados antes del 1/3/20 fue significativamente menor que la de los pacientes enrolados en forma posterior (9% versus 36%) (18) . Los pacientes con COVID-19 severa y los no sobrevivientes presentaron un riesgo significativamente mayor de desarrollar IRA y de necesidad de TRR (18) . Muchas series reportadas posteriormente muestran una disminución en el tiempo de la incidencia y severidad de la IRA asociada a COVID-19 que puede estar relacionada a optimización del tratamiento, a un reconocimiento creciente de formas menos severa de IRA, a la virulencia de las diferentes cepas y a la vacunación (13,(19)(20)(21) .…”